BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 29024241)

  • 1. Sentinel node biopsy in ductal carcinoma in situ of the breast: Never justified?
    Sorrentino L; Sartani A; Bossi D; Amadori R; Nebuloni M; Truffi M; Bonzini M; Riggio E; Foschi D; Corsi F
    Breast J; 2018 May; 24(3):325-333. PubMed ID: 29024241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Necessity of sentinel lymph node biopsy in ductal carcinoma in situ patients: a retrospective analysis.
    Shin YD; Lee HM; Choi YJ
    BMC Surg; 2021 Mar; 21(1):159. PubMed ID: 33752671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variations in the management of the axilla in screen-detected ductal carcinoma in situ: evidence from the UK NHS breast screening programme audit of screen detected DCIS.
    Nicholson S; Hanby A; Clements K; Kearins O; Lawrence G; Dodwell D; Bishop H; Thompson A;
    Eur J Surg Oncol; 2015 Jan; 41(1):86-93. PubMed ID: 25441934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit.
    Moore KH; Sweeney KJ; Wilson ME; Goldberg JI; Buchanan CL; Tan LK; Liberman L; Turner RR; Lagios MD; Cody Iii HS; Giuliano AE; Silverstein MJ; Van Zee KJ
    Ann Surg Oncol; 2007 Oct; 14(10):2911-7. PubMed ID: 17597346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors of axillary positive sentinel lymph node biopsy in extended ductal carcinoma in situ treated by simple mastectomy at once.
    Hotton J; Salleron J; Rauch P; Buhler J; Pierret M; Baumard F; Leufflen L; Marchal F
    J Gynecol Obstet Hum Reprod; 2020 Mar; 49(3):101641. PubMed ID: 31562936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ductal carcinoma in situ: value of sentinel lymph node biopsy.
    Sakr R; Barranger E; Antoine M; Prugnolle H; Daraï E; Uzan S
    J Surg Oncol; 2006 Oct; 94(5):426-30. PubMed ID: 16967457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Sentinel Lymph Node Biopsy Necessary for Ductal Carcinoma In Situ Patients Undergoing Mastectomy?
    Miller-Ocuin JL; Howard-McNatt M; Levine EA; Chiba A
    Am Surg; 2020 Aug; 86(8):955-957. PubMed ID: 32862671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sentinel lymph node biopsy is not necessary in patients diagnosed with ductal carcinoma in situ of the breast by stereotactic vacuum-assisted biopsy.
    Kotani H; Yoshimura A; Adachi Y; Ishiguro J; Hisada T; Ichikawa M; Gondou N; Hattori M; Kondou N; Sawaki M; Fujita T; Iwata H
    Breast Cancer; 2016 Mar; 23(2):190-4. PubMed ID: 24989112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sentinel Node Procedure Obsolete in Lumpectomy for Ductal Carcinoma In Situ.
    Heymans C; van Bastelaar J; Visschers RGJ; Vissers YLJ
    Clin Breast Cancer; 2017 Jun; 17(3):e87-e93. PubMed ID: 28162949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ.
    Coromilas EJ; Wright JD; Huang Y; Feldman S; Neugut AI; Chen L; Hershman DL
    JAMA Oncol; 2015 Jun; 1(3):323-32. PubMed ID: 26181180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy.
    Watanabe Y; Anan K; Saimura M; Koga K; Fujino M; Mine M; Tamiya S; Nishihara K; Nakano T; Mitsuyama S
    Breast Cancer; 2018 Nov; 25(6):663-670. PubMed ID: 29786772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends and clinicopathological predictors of axillary evaluation in ductal carcinoma in situ patients treated with breast-conserving therapy.
    Huang NS; Si J; Yang BL; Quan CL; Chen JJ; Wu J
    Cancer Med; 2018 Jan; 7(1):56-63. PubMed ID: 29271113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does sentinel lymph node biopsy for screening high-grade ductal carcinoma in situ of the breast cause more harm than good?
    Ramzi S; Najeeb E; Coulthard J; Jenkins S
    Breast Cancer Res Treat; 2020 Jul; 182(1):47-54. PubMed ID: 32430678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy.
    Chin-Lenn L; Mack LA; Temple W; Cherniak W; Quinn RR; Ravani P; Lewin AM; Quan ML
    Ann Surg Oncol; 2014 Jan; 21(1):66-73. PubMed ID: 24046105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Axillary evaluation is not warranted in patients preoperatively diagnosed with ductal carcinoma in situ by core needle biopsy.
    Si J; Guo R; Huang N; Xiu B; Zhang Q; Chi W; Wu J
    Cancer Med; 2019 Dec; 8(18):7586-7593. PubMed ID: 31660702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of invasive breast cancer and lymph node involvement in ductal carcinoma in situ initially diagnosed by vacuum-assisted breast biopsy: experience of 733 cases.
    Trentin C; Dominelli V; Maisonneuve P; Menna S; Bazolli B; Luini A; Cassano E
    Breast; 2012 Oct; 21(5):635-40. PubMed ID: 22795363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A N0 Predicting Model for Sentinel Lymph Node Biopsy Omission in Early Breast Cancer Upstaged From Ductal Carcinoma in Situ.
    Yoo TK; Kim SJ; Lee J; Lee SB; Lee SJ; Park HY; Park HK; Chae BJ; Eom YH; Kim HS; Song BJ
    Clin Breast Cancer; 2020 Jun; 20(3):e281-e289. PubMed ID: 32147404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of underestimated invasiveness in patients with ductal carcinoma in situ of the breast on percutaneous biopsy as rationale for recommending concurrent sentinel lymph node biopsy.
    Schulz S; Sinn P; Golatta M; Rauch G; Junkermann H; Schuetz F; Sohn C; Heil J
    Breast; 2013 Aug; 22(4):537-42. PubMed ID: 23237921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel lymph node positivity in patients undergoing mastectomies for ductal carcinoma in situ (DCIS).
    Price A; Schnabel F; Chun J; Kaplowitz E; Goodgal J; Guth A; Axelrod D; Shapiro R; Mema E; Moy L; Darvishian F; Roses D
    Breast J; 2020 May; 26(5):931-936. PubMed ID: 31957944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superparamagnetic iron oxide (SPIO) for axillary mapping in patients with ductal carcinoma in situ undergoing mastectomy: single-institution experience.
    Addae JK; Sweeting RS; Meszoely IM; McCaffrey RL; Kauffmann RM; Kelley MC; Grau AM; Hewitt K
    Breast Cancer Res Treat; 2024 Feb; 204(1):117-121. PubMed ID: 38087058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.